# US 2021/0260177 A1 · Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260177 A1
- Document ID: US20210260177A1
- Status: Published application
- Kind: A1
- Application number: 17/241,603
- Filed: 2021-04-27
- Published: 2021-08-26
- Earliest claimed: 2015-07-21
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Wendy Jo Watson; Luis Pascual Jodar Martin-Montalvo; Raul Enrique Isturiz; Ralf Rene Reinert
- Web page: https://patentgrep.com/patent/US20210260177A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08B 37/006: {Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof}
- C08H 1/00: Macromolecular products derived from proteins (food proteins A23; glue, gelatine C09H)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08H: DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS (polysaccharides C08B; natural rubber C08C; natural resins or their derivatives C09F; bituminous materials C10)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

## Claims

### Claim 1

A kit comprising: (a) a first immunogenic composition comprising at least one glycoconjugate selected from the group consisting of a glycoconjugate from Streptococcus pneumoniae serotype 15B, a glycoconjugate from S. pneumoniae serotype 22F, a glycoconjugate from S. pneumoniae serotype 33F, a glycoconjugate from S. pneumoniae serotype 12F, a glycoconjugate from S. pneumoniae serotype 10A, a glycoconjugate from S. pneumoniae serotype 11A and a glycoconjugate from S. pneumoniae serotype 8, wherein said composition is a 1, 2, 3, 4, 5, 6 or 7-valent pneumococcal conjugate composition; and (b) a second immunogenic composition comprising at least one glycoconjugate from an S. pneumoniae serotype selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F for simultaneous, concurrent, concomitant or sequential administration of the first and second immunogenic compositions.

### Claim 2 (depends on 1)

The kit of claim 1, wherein said first immunogenic composition comprises a glycoconjugate from S. pneumoniae serotype 15B, a glycoconjugate from S. pneumoniae serotype 22F, a glycoconjugate from S. pneumoniae serotype 33F, a glycoconjugate from S. pneumoniae serotype 12F, a glycoconjugate from S. pneumoniae serotype 10A, a glycoconjugate from S. pneumoniae serotype 11A and a glycoconjugate from S. pneumoniae serotype 8, and wherein said composition is a 7-valent pneumococcal conjugate composition.

### Claim 3 (depends on 1)

The kit of claim 1, wherein said at least one glycoconjugate of said first immunogenic composition is individually conjugated to CRM197.

### Claim 4 (depends on 1)

The kit of claim 1, wherein said first immunogenic composition further comprises an adjuvant.

### Claim 5 (depends on 1)

The kit of claim 1, wherein said second immunogenic composition comprises glycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.

### Claim 6 (depends on 5)

The kit of claim 5, wherein said glycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F are conjugated to CRM197.

### Claim 7 (depends on 1)

The kit of claim 1, wherein said second immunogenic composition comprises glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.

### Claim 8 (depends on 7)

The kit of claim 7, wherein said glycoconjugates from S. pneumoniae serotypes 1, 5 and 7F are conjugated to CRM197.

### Claim 9 (depends on 7)

The kit of claim 7, wherein said glycoconjugate from S. pneumoniae serotype 18C is conjugated to tetanus toxoid (TT).

### Claim 10 (depends on 7)

The kit of claim 7, wherein said glycoconjugate from S. pneumoniae serotype 19F is conjugated to diphtheria toxoid (DT).

### Claim 11 (depends on 7)

The kit of claim 7, wherein said glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F are individually conjugated to Haemophilus influenzae protein D (PD).

### Claim 12 (depends on 7)

The kit of claim 7, wherein said glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14 and/or 23F are individually conjugated to PD, said glycoconjugate from S. pneumoniae serotype 18C is conjugated to TT and said glycoconjugate from S. pneumoniae serotype 19F is conjugated to DT.

### Claim 13 (depends on 1)

The kit of claim 1, wherein said second immunogenic composition comprises glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

### Claim 14 (depends on 13)

The kit of claim 13, wherein said glycoconjugates from S. pneumoniae serotypes 3, 6A and 19A are conjugated to CRM197.

### Claim 15 (depends on 13)

The kit of claim 13, wherein said glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F are conjugated to CRM197.

### Claim 16 (depends on 1)

The kit of claim 1, wherein said second immunogenic composition is a 7, 8, 9, 10, 11, 12, 13, 14 or 15-valent pneumococcal conjugate composition.

### Claim 17 (depends on 1)

The kit of claim 1, wherein said second immunogenic composition is a 13-valent pneumococcal conjugate composition consisting of glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM197.

### Claim 18 (depends on 1)

The kit of claim 1, wherein said second immunogenic composition further comprises an adjuvant.

### Claim 19 (depends on 1)

The kit of claim 1, wherein the first and second immunogenic compositions are administered simultaneously.

### Claim 20 (depends on 1)

The kit of claim 1, wherein a schedule of vaccination for said simultaneous administration is a multiple dose schedule.

### Claim 21 (depends on 20)

The kit of claim 20, wherein said multiple dose schedule comprises at least one dose in the first year of age followed by at least one toddler dose.

### Claim 22 (depends on 1)

The kit of claim 1, wherein the first and second immunogenic compositions are administered concomitanly.

### Claim 23 (depends on 1)

The kit of claim 1, wherein a schedule of vaccination for said concomitant administration is a multiple dose schedule.

### Claim 24 (depends on 22)

The kit of claim 22, wherein said multiple dose schedule comprises at least one dose in the first year of age followed by at least one toddler dose.

### Claim 25 (depends on 1)

The kit of claim 1, wherein the first and second immunogenic compositions are administered concurrently.

### Claim 26 (depends on 1)

The kit of claim 1, wherein a schedule of vaccination for said concurrent administration is a multiple dose schedule.

### Claim 27 (depends on 26)

The kit of claim 26, wherein said multiple dose schedule comprises at least one dose in the first year of age followed by at least one toddler dose.

### Claim 28 (depends on 1)

The kit of claim 1, wherein the first and second immunogenic compositions are administered sequentially.

### Claim 29 (depends on 28)

The kit of claim 28, wherein a schedule of vaccination for said sequential administration comprises a series of 2, 3, 4, 5, 6, 7 or 8 doses.

### Claim 30 (depends on 28)

The kit of claim 28, wherein a schedule of vaccination comprises the sequential administration of:
(a) the first immunogenic composition and
(b) concomitant or concurrent administration of the first immunogenic composition with the second immunogenic composition.

### Claim 31 (depends on 28)

The kit of claim 28, wherein a schedule of vaccination comprises the sequential administration of:
(a) the second immunogenic composition and
(b) concomitant or concurrent administration of the first immunogenic composition with the second immunogenic composition.
